Skip to content

The Pathophysiology of Orthostatic Hypotension

The Pathophysiology of Orthostatic Hypotension

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00748059
Enrollment
10
Registered
2008-09-08
Start date
1996-12-31
Completion date
2020-12-31
Last updated
2021-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autonomic Nervous System Diseases, Orthostatic Hypotension, Dopamine Beta-Hydroxylase Deficiency, Orthostatic Intolerance

Keywords

autonomic nervous system diseases, blood pressure, congenital, orthostasis, catecholamines

Brief summary

The purpose of this study is to determine the cause of low blood pressure in selective patients who have problems with their involuntary (autonomic) nervous system. These patients frequently have had symptoms throughout their life, and their disorder might have a genetic basis. The biochemical, physiological and pharmacological procedures in this study should help us define the problem and perhaps lead to more effective treatment.

Interventions

PROCEDUREStanding or upright tilt

stand upright or tilt table test

Recording from sympathetic nerve

PROCEDUREQSweat

quantitative sweat testing

DEVICEneck cuff stimulation

Blood pressure receptors in the neck arteries may be stimulated by applying suction through a collar around the neck.

DRUGphenylephrine,isoproterenol,nitroprusside,propranolol,edrophonium,atropine,tyramine

IV Pharmacological Testing phenylephrine 12.5 - 400 ug, isoproterenol 0.1 - 0.4 ug or higher until desired effect, nitroprusside 0.1 - 1.6 ug/kg, propranolol 1.1 mg/min, edrophonium maximum of 10 mg, atropine .01 mg/kg, tyramine 250-4000 ug or higher until desired effect

DRUGclonidine,yohimbine,metoclopramide,alpha-methyldopa

Oral Pharmacological Testing clonidine 0.1-0.3 mg, yohimbine 5-10 mg, metoclopramide 10 mg, alpha-methyldopa 62.5 mg, placebo

PROCEDUREBodPod

Determination of body composition

PROCEDUREEye exam

Examination of pressure in the eye and eyelid fatiguability. The following eyedrops might be used: 1. 0.5% proparacaine (Alcaine, Allergan, Inc) 2. Fluress (0.4% benoxinate hydrochloride, fluorescein sodium, Akorn, Inc) 3. 0.5%, 1% tropicamide (Mydriacyl, Alcon) 4. Over-the-counter preservative-free artificial tears 5. 0.25%, 2.5% and 10% phenylephrine (Bausch and Lomb) 6. 1% cyclopentolate hydrochloride (Alcon)

PROCEDURESleep study

Recording of sleep pattern overnight

PROCEDUREPain response testing

Subjects will rate the quality and intensity of 2 pain tasks.

Determination of metabolic rate via 24hr stay in whole-room indirect calorimeter

PROCEDUREBrain function studies

Questionnaires and computer tasks, an EEG and an MRI may be used to assess brain function.

PROCEDUREBicycle Exercise Test

Blood pressure and heart rate may be monitored while exercising on a stationary bicycle.

Sponsors

Vanderbilt University Medical Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
12 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* severe orthostatic hypotension and other autonomic symptoms but do not meet criteria for standard diagnosis * non-smokers * drug-free * able to give informed consent * free of pulmonary, renal, hematopoietic, hepatic and cardiac disease

Exclusion criteria

* medications affecting the autonomic nervous system * any chronic illness * anemia (Hct\<30) * women of childbearing age who are pregnant or nursing * smokers

Design outcomes

Primary

MeasureTime frame
hemodynamic changes with standingfollowing test

Secondary

MeasureTime frame
Pain responseonce
Responses on questionnaires and computer tasks designed to assess brain functiononce
sympathetic nerve activityduring stimulation of sympathetic nervous system
quantitative sweat testing2 hours
Metabolic rateonce
blood and urine hormonesafter test
blood volumeduring supine and/or upright postures
Sleep efficiencyonce
Eye functiononce

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026